Subconjunctival aflibercept

Phase 1Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Corneal Neovascularization

Conditions

Corneal Neovascularization

Trial Timeline

Jun 1, 2013 → Oct 1, 2015

NCT ID

NCT01868360

About Subconjunctival aflibercept

Subconjunctival aflibercept is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Corneal Neovascularization. The current trial status is terminated. This product is registered under clinical trial identifier NCT01868360. Target conditions include Corneal Neovascularization.

What happened to similar drugs?

3 of 4 similar drugs in Corneal Neovascularization were approved

Approved (3) Terminated (1) Active (0)

✅0.3% hypromelloseNovartisApproved

✅Mycophenolate Mofetil 2x 1gRocheApproved

✅loteprednol etabonate 0.25% ophthalmic suspensionKala PharmaceuticalsApproved

❌riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL systemGlaukosPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01868360	Phase 1	Terminated	Jun 1, 2013	Oct 1, 2015	Corneal Neovascularization

Competing Products

12 competing products in Corneal Neovascularization

See all competitors

Product	Company	Stage	Hype Score
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	35
Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1%	AbbVie	Phase 2	35
0.3% hypromellose	Novartis	Approved	43
Mycophenolate Mofetil 2x 1g	Roche	Approved	43
riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system	Glaukos	Phase 3	29
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)	Glaukos	Phase 2	24
lufepirsen high dose + Vehicle + lufepirsen low dose	Glaukos	Phase 2	39
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo	Oculis Holding AG	Phase 2	29
DT-168	Design Therapeutics	Phase 2	36
KPI-012 + KPI-012 Vehicle	Kala Pharmaceuticals	Phase 2	17
loteprednol etabonate 0.25% ophthalmic suspension	Kala Pharmaceuticals	Approved	33
QR-504a	ProQR	Phase 1	11